VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
VOLITIONRX LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.17−0.01 (-3.50%)
Close on Oct 19, 2026
- Market cap
- $1.59M
- P/E (TTM)
- –
- Dividend yield
- –
Volitionrx statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Volitionrx | Industry median |
|---|---|---|
| Market Cap | $2.37M | $197.05M |
| Enterprise Value | $5.25M | $106.56M |
| PS Ratio | 0.97 | 3.93 |
Enterprise value
| Measure | Volitionrx | Industry median |
|---|---|---|
| EV / Sales | 2.14 | 2.69 |
Income (trailing twelve months)
| Measure | Volitionrx | Industry median |
|---|---|---|
| Revenue | $2.46M | $57.94M |
| Operating Income | -$19.42M | -$21.44M |
| Net Income | -$25.64M | -$22.46M |
| EBITDA | -$18.55M | -$16.91M |
| EPS (Diluted) | -$3.86 | -$0.83 |
Margins
| Measure | Volitionrx | Industry median |
|---|---|---|
| Operating Margin | -790.2% | -44.5% |
| Profit Margin | -1043.1% | -39.2% |
| EBITDA Margin | -754.7% | -31.3% |
| FCF Margin | -796.7% | -8.85% |
Returns
| Measure | Volitionrx | Industry median |
|---|---|---|
| Return on Assets (ROA) | -301.5% | -41.0% |
Growth
| Measure | Volitionrx | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 86.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 78.0% | 2.25% |
| Revenue Growth (5Y CAGR) | 164.1% | 6.42% |
Balance sheet
| Measure | Volitionrx | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.80M | $62.42M |
| Total Debt | $7.05M | $120.13M |
| Net Cash (Debt) | -$4.25M | $15.68M |
| Net Cash Per Share | -$0.31 | $0.65 |
| Equity (Book Value) | -$32.16M | $48.79M |
| Book Value Per Share | -$2.36 | $1.36 |
| Tangible Book Value | -$32.47M | $23.06M |
| Working Capital | -$9.40M | $75.77M |
Financial position
| Measure | Volitionrx | Industry median |
|---|---|---|
| Current Ratio | 0.30 | 3.30 |
| Quick Ratio | 0.23 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Volitionrx | Industry median |
|---|---|---|
| Operating Cash Flow | -$19.56M | -$12.35M |
| Capital Expenditures | -$21.97K | -$1.06M |
| Free Cash Flow | -$19.58M | -$20.28M |
| FCF Per Share | -$1.43 | -$0.41 |
Efficiency
| Measure | Volitionrx | Industry median |
|---|---|---|
| Asset Turnover | 0.29 | 0.38 |
| Revenue Per Employee | $32.77K | $398.96K |
| Profits Per Employee | -$341.87K | -$732.08K |
| Employee Count | 75 | 73 |
Dividends and yields
| Measure | Volitionrx | Industry median |
|---|---|---|
| Earnings Yield | -1080.8% | -21.2% |
| FCF Yield | -825.6% | -7.64% |
| Buyback Yield | -814.9% | -0.58% |
| Shareholder Yield | -814.9% | 0.00% |
Shares
| Measure | Volitionrx | Industry median |
|---|---|---|
| Shares Outstanding | 13,649,400 | 59,128,900 |
| Shares Change (YoY) | 44.5% | 11.1% |
| Shares Change (QoQ) | 51.9% | 0.54% |
| Shares Held by Institutions | 14.1% | 59.4% |
Scores
| Measure | Volitionrx | Industry median |
|---|---|---|
| Altman Z-Score | -53.84 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Volitionrx's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.